Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Implant Sciences

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of 1 mil. units at $7.50 each is effective June 25, with trading beginning on the Nasdaq smallcap market and the Boston Stock Exchange. Each unit consists of one share of common stock and one redeemable common stock purchase warrant. The Wakefield, Massachusetts firm recently received 510(k) clearance for its I-Plant iodine-125 radioactive seed for the treatment of prostate cancer and plans to use the IPO proceeds to ramp up production and staff, expand R&D, increase sales and marketing efforts, and for general corporate purposes. Implant Sciences, which develops products and processes for use of ion implantation and thin film coatings of radioactive and non-radioactive materials, also is working on radioactive coronary stents and interventional cardiology devices for prevention of restenosis. Westport Resources Investment Services was lead underwriter for the offering. Co-managers included Schneider Securities and Weatherly Securities Corporation
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT012009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel